Given their joint undertakings and the synergies that could potentially be generated, grouping of Epygon, Kardiozis, Kephalios and MyoPowers, to create Affluent Medical.
Formation of the Company and operation of contributions in kind of all the shares and convertible bonds issued by Epygon, Kephalios, Kardiozis and MyoPowers to the Company.
Transformation of the Company (incorporated as a simplified joint-stock company) into a public limited company with a Board of Directors on March 27, 2018.
Kalios™ and Artus enter into the clinical trial phase.
Receipt of the “innovative company” label from Bpifrance on April 25, 2018.